发明新疗法而不重蹈覆辙：药物再利用的力量。
Inventing new therapies without reinventing the wheel: the power of drug repurposing.
机构信息
Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Clinical, Experimental Surgery and Translational Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
出版信息
Br J Pharmacol. 2018 Jan;175(2):165-167. doi: 10.1111/bph.14081.
Abstract
This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
摘要
这篇文章是“发明新药无需另起炉灶：药物重定位的力量”专题的一部分。要查看本部分的其他文章，请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.。
相似文献
1
Inventing new therapies without reinventing the wheel: the power of drug repurposing.发明新疗法而不重蹈覆辙：药物再利用的力量。
Br J Pharmacol. 2018 Jan;175(2):165-167. doi: 10.1111/bph.14081.
2
Drug repurposing from the perspective of pharmaceutical companies.从制药公司的角度看药物再利用。
Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18.
3
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.聚腺苷二磷酸核糖聚合酶抑制剂在非肿瘤性疾病治疗中的再利用机会。
Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26.
4
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.针对磷酸二酯酶 5 作为治疗心肌缺血/再灌注损伤和心力衰竭的一种治疗选择。
Br J Pharmacol. 2018 Jan;175(2):223-231. doi: 10.1111/bph.13749. Epub 2017 Mar 23.
5
Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism.将一种新型甲状旁腺激素类似物重新用于治疗甲状旁腺功能减退症。
Br J Pharmacol. 2018 Jan;175(2):262-271. doi: 10.1111/bph.14028. Epub 2017 Nov 28.
6
Drug repurposing screens and synergistic drug-combinations for infectious diseases.药物重定位筛选和传染病协同药物组合。
Br J Pharmacol. 2018 Jan;175(2):181-191. doi: 10.1111/bph.13895. Epub 2017 Jul 9.
7
Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.拉伸诱导的神经创伤模型的建立用于体外高通量筛选：利福平作为神经保护剂的鉴定。
Br J Pharmacol. 2018 Jan;175(2):284-300. doi: 10.1111/bph.13642. Epub 2016 Nov 15.
8
Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.奥拉帕利可保护心肌细胞免受氧化应激，并改善大鼠心脏移植后早期移植物的收缩性。
Br J Pharmacol. 2018 Jan;175(2):246-261. doi: 10.1111/bph.13983. Epub 2017 Oct 2.
9
The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.临床上使用的 PARP 抑制剂奥拉帕利可改善三度烧伤模型鼠的器官功能，抑制炎症反应，加速伤口愈合。
Br J Pharmacol. 2018 Jan;175(2):232-245. doi: 10.1111/bph.13735. Epub 2017 Mar 5.
10
β-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice.β-石竹烯通过减轻小鼠炎症和代谢紊乱来预防酒精性脂肪性肝炎。
Br J Pharmacol. 2018 Jan;175(2):320-334. doi: 10.1111/bph.13722. Epub 2017 Feb 22.
引用本文的文献
1
New insights on Drug's design against candidiasis on the fructose biphosphate aldolase (Fba1) and the pyruvate kinase (Pk) of .关于针对念珠菌病设计的药物对果糖二磷酸醛缩酶（Fba1）和丙酮酸激酶（Pk）的新见解。
Biochem Biophys Rep. 2025 Jul 25;43:102175. doi: 10.1016/j.bbrep.2025.102175. eCollection 2025 Sep.
2
The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders.微生物群-肠道-脑轴理论：肠道微生物群调节剂（GMMs）在胃肠道、神经和精神疾病中的作用。
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 5. doi: 10.1007/s00210-025-04155-2.
3
Discovery of novel antifungal drugs via screening repurposing libraries against spherule initials.通过针对球状体初始物筛选重新利用文库发现新型抗真菌药物。
mBio. 2025 May 14;16(5):e0020525. doi: 10.1128/mbio.00205-25. Epub 2025 Mar 26.
4
Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trials.极光激酶B抑制剂AZD1152：基于临床试验结果用于狼疮性肾炎治疗的重新定位
EBioMedicine. 2025 Feb;112:105553. doi: 10.1016/j.ebiom.2024.105553. Epub 2025 Jan 11.
5
Drug repurposing for glomerular diseases: an underutilized resource.药物再利用治疗肾小球疾病：未充分利用的资源。
Nat Rev Nephrol. 2024 Nov;20(11):707-721. doi: 10.1038/s41581-024-00864-8. Epub 2024 Jul 31.
6
Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients.发现非癌症药物的潜力：多发性骨髓瘤患者的一项突破性进展。
Cancers (Basel). 2024 Jun 28;16(13):2381. doi: 10.3390/cancers16132381.
7
Predictions of Colloidal Molecular Aggregation Using AI/ML Models.使用人工智能/机器学习模型预测胶体分子聚集
ACS Omega. 2024 Jun 18;9(26):28691-28706. doi: 10.1021/acsomega.4c02886. eCollection 2024 Jul 2.
8
Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.胶粒聚集使基于细胞的新冠病毒抗病毒筛选复杂化。
J Med Chem. 2024 Jun 27;67(12):10263-10274. doi: 10.1021/acs.jmedchem.4c00597. Epub 2024 Jun 12.
9
Colloidal aggregation confounds cell-based Covid-19 antiviral screens.胶体聚集干扰了基于细胞的新冠病毒抗病毒筛选。
bioRxiv. 2023 Oct 30:2023.10.27.564435. doi: 10.1101/2023.10.27.564435.
10
Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells.非肿瘤药物（美替卡韦）与表观遗传抑制剂协同显示出抗癌能力，并且似乎被动参与靶向癌细胞。
Front Oncol. 2023 May 19;13:1157366. doi: 10.3389/fonc.2023.1157366. eCollection 2023.
本文引用的文献
1
Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism.将一种新型甲状旁腺激素类似物重新用于治疗甲状旁腺功能减退症。
Br J Pharmacol. 2018 Jan;175(2):262-271. doi: 10.1111/bph.14028. Epub 2017 Nov 28.
2
Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.奥拉帕利可保护心肌细胞免受氧化应激，并改善大鼠心脏移植后早期移植物的收缩性。
Br J Pharmacol. 2018 Jan;175(2):246-261. doi: 10.1111/bph.13983. Epub 2017 Oct 2.
3
Drug repurposing screens and synergistic drug-combinations for infectious diseases.药物重定位筛选和传染病协同药物组合。
Br J Pharmacol. 2018 Jan;175(2):181-191. doi: 10.1111/bph.13895. Epub 2017 Jul 9.
4
Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation.布洛芬和双氯芬酸治疗可减少炎症损伤和有丝分裂刺激时胰腺腺泡细胞的增殖。
Br J Pharmacol. 2018 Jan;175(2):335-347. doi: 10.1111/bph.13867. Epub 2017 Jun 16.
5
Glycogen phosphorylase inhibition improves beta cell function.糖原磷酸化酶抑制可改善β细胞功能。
Br J Pharmacol. 2018 Jan;175(2):301-319. doi: 10.1111/bph.13819. Epub 2017 Jun 18.
6
Drug repurposing from the perspective of pharmaceutical companies.从制药公司的角度看药物再利用。
Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18.
7
Dexpramipexole improves bioenergetics and outcome in experimental stroke.地昔帕明改善实验性中风中的生物能量和预后。
Br J Pharmacol. 2018 Jan;175(2):272-283. doi: 10.1111/bph.13790. Epub 2017 May 12.
8
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.针对磷酸二酯酶 5 作为治疗心肌缺血/再灌注损伤和心力衰竭的一种治疗选择。
Br J Pharmacol. 2018 Jan;175(2):223-231. doi: 10.1111/bph.13749. Epub 2017 Mar 23.
9
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.聚腺苷二磷酸核糖聚合酶抑制剂在非肿瘤性疾病治疗中的再利用机会。
Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26.
10
The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.临床上使用的 PARP 抑制剂奥拉帕利可改善三度烧伤模型鼠的器官功能，抑制炎症反应，加速伤口愈合。
Br J Pharmacol. 2018 Jan;175(2):232-245. doi: 10.1111/bph.13735. Epub 2017 Mar 5.
Zotero 插件